March 1, 2021

To, The Manager
BSE Limited
Department of Corporate Services
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001

To, The Manager
National Stock Exchange of India Limited
Corporate Communication Department
Exchange Plaza, Bandra Kurla Complex
Mumbai – 400 050

Scrip Code – 532523

Scrip Symbol - Biocon

Subject: Press Release titled “Biocon Biologics Promotes Shreehas Tambe to Deputy Chief Executive Officer”.

Dear Sir/Madam,

Please find enclosed the press release titled “Biocon Biologics Promotes Shreehas Tambe to Deputy Chief Executive Officer”.

The above information will also be available on the website of the Company at www.biocon.com.

Kindly take the same on record and acknowledge.

Thanking You,

Yours faithfully,

For Biocon Limited

Mayank Verma
Company Secretary and Compliance Officer
PRESS RELEASE

Biocon Biologics Promotes Shreehas Tambe to Deputy Chief Executive Officer

Bengaluru, India; March 1, 2021:

Biocon Biologics Ltd., a fully integrated ‘pure play’ biosimilars company and a subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), announced today that Mr Shreehas Tambe has been promoted to the position of Deputy Chief Executive Officer of Biocon Biologics Limited w.e.f. March 1, 2021.

A Biocon veteran, Shreehas joined Biocon in 1997 and has, since then, taken on positions of increasing responsibility. He has over 20 years of leadership experience in operational and strategic roles and has led large, diverse teams at R&D, Manufacturing and Projects & Engineering during his tenure. Shreehas began his professional journey at Biocon as a Management Trainee starting out in the R&D department, where he led the design and development of a novel bioreactor, the PlaFractor™, a unique solid state bioreactor that got Biocon its first U.S. patent and went on to win the National Award for the Best Technology of the Year in 2001.

Prior to becoming the Deputy CEO, Shreehas was the Chief Operating Officer and a key member of the Executive Leadership Team at Biocon Biologics. Previously, as the Senior Vice President & Global Head of Biocon’s Insulins business unit he was responsible for the P&L and expanding the Insulins portfolio across several geographies. He led the development, approval and launch of Insulin analogs in Japan and later in EU and U.S. The insulins franchise showed strong performance in emerging markets led by sales in Mexico, Malaysia and Latin America.

Kiran Mazumdar-Shaw, Executive Chairperson, Biocon Biologics, said: “I am delighted to welcome Shreehas Tambe in his new role as the Deputy CEO of Biocon Biologics. During his more than two decade-long career with Biocon, Shreehas has exhibited strong leadership in his diverse roles at R&D, Manufacturing and Projects & Engineering. Shreehas has also worked closely with Dr Arun Chandavarkar, Managing Director of Biocon Biologics, on formulating business strategies and achieving operational excellence. I believe the combination of Arun and Shreehas in their new roles along with the rest of the leadership team will enable Biocon Biologics to capitalize on the promising biosimilars opportunity to pursue its high growth trajectory.”
Dr Arun Chandavarkar, Managing Director, Biocon Biologics said: “I would like to congratulate Shreehas Tambe for his new role as the Deputy CEO of Biocon Biologics. Shreehas has played a critical role in shaping our biosimilars business over the years in different roles and more recently as the COO of Biocon Biologics. As a key member of the various committees looking at governance, investments and strategic collaborations, Shreehas has leveraged his domain knowledge and the technical & functional expertise to contribute towards making Biocon Biologics a global leader. Biocon Biologics is built on strong business fundamentals and I am confident Shreehas will use his expertise and leadership skills to enable his teams to deliver robust growth and reaffirm their commitment to impact millions of patients’ lives globally.”

Shreehas Tambe, Deputy Chief Executive Officer, Biocon Biologics said: “I am deeply honored to take on this role to drive Biocon Biologics towards becoming a global leader in affordable healthcare. I am humbled by the faith placed in me by Biocon Biologics’ leadership and the Board members. Along with the leadership team, I am looking forward to realising the several opportunities that lie ahead of us and work collaboratively to address challenges. We have a proven track record of scientific credibility, global scale, highest standards of quality and governance, which give me the confidence that along with our partners and customers we will successfully deliver on our vision to make healthcare accessible to benefit millions of patients and their families across the world.”

It was under Shreehas’ leadership that Biocon made its first overseas investment in R&D and Manufacturing in 2015, building Asia’s largest integrated insulins complex in Malaysia, which is approved by the U.S. FDA and EMA among other regulatory agencies. Shreehas was the Global Head of Projects & Engineering when he led the multi-million dollar investment in Malaysia, managing and providing strategic direction to the investment.

He holds a Masters’ degree in Bioprocess Technology from ICT (UDCT), University of Mumbai and has also studied Pharmaceutical Sciences & Technology at University of Pune. He was conferred the coveted Distinguished Alumnus Award (Professional) by his alma mater, the prestigious ICT, Mumbai, in 2020.

About Biocon Biologics Limited:

Biocon Biologics Limited, a subsidiary of Biocon Limited is uniquely positioned as a fully integrated ‘pure play’ biosimilars organization in the world. Building on the four pillars of Patients, People, Partners and Business, Biocon Biologics is committed to transforming healthcare and transforming lives. Biocon Biologics is leveraging cutting-edge science, innovative tech platforms and advanced research & development capabilities to lower treatment costs while improving healthcare outcomes. It has a platform of 28 biosimilar molecules across diabetes, oncology, immunology, dermatology, ophthalmology, neurology, rheumatology and inflammatory diseases. Five molecules from Biocon
Biologics’ portfolio have been taken from lab to market, of which three have been commercialized in developed markets like United States, EU, Australia, Canada and Japan. With a team of over 4,800 people Biocon Biologics aspires to transform healthcare through affordable innovative solutions as well as impact 5 million patients’ lives by FY 22.

**Biocon Biologics on the Web**; Follow-us on Twitter: [@BioconBiologics](https://twitter.com/BioconBiologics)

**About Biocon Limited:**
Biocon Limited, publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is an innovation-led global biopharmaceuticals company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as generic formulations in the US and Europe. It also has a pipeline of promising novel assets in immunotherapy under development. **Website:** [www.biocon.com](http://www.biocon.com); Follow-us on Twitter: [@bioconlimited](https://twitter.com/bioconlimited)

<table>
<thead>
<tr>
<th>FOR MORE INFORMATION</th>
<th>INVESTOR RELATIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MEDIA RELATIONS</strong></td>
<td><strong>INKUNJ MALL</strong></td>
</tr>
<tr>
<td>Seema Ahuja</td>
<td>Head, Investor Relations, Biocon Biologics</td>
</tr>
<tr>
<td>Sr. VP &amp; Global Head of Communications &amp; Corporate Brand</td>
<td>📞 +91 80 2808 2222</td>
</tr>
<tr>
<td><a href="https://biocon.com">Biocon Group &amp; Biocon Biologics</a></td>
<td>📞 +91 99723 17792</td>
</tr>
<tr>
<td>📞 +91 80 2808 2222</td>
<td>✉️ <a href="mailto:seema.ahuja@biocon.com">seema.ahuja@biocon.com</a></td>
</tr>
<tr>
<td>✉️ <a href="mailto:seema.ahuja@biocon.com">seema.ahuja@biocon.com</a></td>
<td>✉️ <a href="mailto:nikunj.mall@biocon.com">nikunj.mall@biocon.com</a></td>
</tr>
</tbody>
</table>

**Forward-Looking Statement:**
This press release may include statements of future expectations and other forward-looking statements based on management’s current expectations and beliefs concerning future developments and their potential effects upon Biocon Limited, Biocon Biologics Limited and its subsidiaries/associates. These forward-looking statements involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from our expectations include, amongst other: general economic and business conditions in India and overseas, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currency changes, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition in and the conditions of the Indian and global biotechnology and pharmaceuticals industries, changes in political conditions in India and changes in the foreign exchange control regulations in India. Neither Biocon Limited, nor Biocon Biologics Limited, nor its Directors, nor any of its subsidiaries/associates assume any obligation to update any particular forward-looking statement contained in this release.